In celebration of International Pathology Day, Trajan Scientific and Medical (Trajan) is proud to announce a new partnership with ScyTek Laboratories (ScyTek) to deliver quality immunohistochemistry (IHC) solutions.
IHC is an important histological and immunological technique used in tumor classification and disease diagnosis, as well as treatment selection. Pathology laboratories carefully prepare patient samples on microscope slides for examination using different antibodies and stains.
With thirty years’ experience manufacturing high quality regents for the global life sciences market, the ScyTek range includes primary antibodies, stains and special stains, and ELISA reagents and components. With over 1,000 products available, ScyTek has something for every laboratory.
Trajan is focused on science that benefits people, to provide quality solutions for laboratories resulting in the best possible outcomes for patients. Trajan’s experience in complete laboratory workflow solutions, and in-depth knowledge of the interaction of microscope slide glass and surface treatments with reagents and biological tissue, ensures selection of the best partners to make a positive impact on wellbeing.
The pairing of ScyTek’s premium quality reagents with Trajan’s Series 2 and 3 adhesive microscope slides provide an ideal combination for difficult specimens, providing optimal adherence and visibility.
ScyTek’s antibodies are available both concentrated and ready-to-use for diagnostic and research use, with the full range offered via Trajan. Please contact us directly to assist you in selecting products to optimize your pathology laboratory workflow.
Share your critical pathology work using the ScyTek range and Trajan microscope slides on International Pathology Day via social media with @trajanscimed @ScyTekLab #IPD2020 #wellbeing #IHCpath #pathology.
Featured ScyTek antibodies
Press release [PDF]
Media contact information
Trajan Scientific and Medical
Trajan Scientific and Medical’s hemaPEN® has been independently evaluated and the results of the study published in the Royal Society of Chemistry’s journal Analyst - selected for the cover of issue 17. hemaPEN demonstrated significant advantages for blood sampling to support better healthcare decision making.
Trajan Scientific and Medical has listed its hemaPEN® blood microsampling device with the U.S. Food and Drug Administration as Class I for therapeutic and in vitro diagnostic use. This follows the hemaPEN’s recent registration in May for supply in the EU and UK as a General IVD; as well as inclusion in the TGA’s ARTG (Australian Register of Therapeutic Goods) in February as a Class I IVD.